Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine has been granted a positive opinion for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia, except acute promyelocytic
MYLOTARG in combination with daunorubicin and cytarabine has been granted a positive opinion for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia, except acute promyelocytic
Over the past few years I have had excellent service from the eye specialists at the Queen Elizabeth Hospital, and in 2016 my younger son was cured of acute promyelocytic
leukaemia by the wonderful cancer specialists at Derby Royal Hospital, so I am in no doubt that, at the clinical level, our health service is, generally speaking, as good as any health service anywhere on this planet.
According to CTI BioPharma Corp, the expected milestone payment is related to the US Food and Drug Administration's approval of TRISENOX (arsenic trioxide) for first line treatment of acute promyelocytic
Kirsten Hawksey, 23, died onChristmas day- four weeks after being diagnosed with Acute Promyelocytic
Kirsten Hawksey, who "idolised" her 15-month-old daughter, Penelope, was diagnosed with acute promyelocytic
leukaemia on November 27.
Arsenic trioxide (ATO) is used as an effective treatment option in promyelocytic
Although acute promyelocytic
leukemia (APL) accounts for 12-15% of therapy-related AML (t-AML), these cases typically occur following chemotherapy with topoisomerase II inhibitor and only occasionally following radiation therapy.
Maths teacher Paul McGeary was diagnosed with relapsed blood cancer, Acute Promyelocytic
Leukaemia (APML), earlier this year, having been in remission from an initial diagnosis in November 2014.
The improved understanding of the effect of vitamin A on the TET2 enzyme also potentially explains why a proportion of patients with acute promyelocytic
leukemia (once considered the deadliest form of acute leukemia) are resistant to effective combination treatment with vitamin A.
The treatment of acute promyelocytic
leukemia (APL) has improved remarkably during the last two decades mainly due to disease-specific drugs, such as all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) [1, 2].
leukemia (APL) and myelodysplastic syndromes (MDS)/therapy-related AML are two subtypes of AML that are especially unique in terms of disease etiology and prognosis, both of which will be discussed in detail in this report.